TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 7.4. It has been cited 314 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.863
From this paper's citation signal
Citation Network Contribution
6.5
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NCI NIH HHS
Grant: P30 CA016672
2019 AACR-Pfizer Immuno-oncology Research Fellowship
Grant: 19-40-49-JIAN
Cancer Prevention and Research Institute of Texas
Grant: RP160710
Breast Cancer Research Foundation
Grant: BCRF-18-070
National Institutes of Health
Grant: CA016672
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
FWCI
16.79
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals